Press release
Alnylam Announces Planned CEO Leadership Transition
− Founding Alnylam CEO John Maraganore to Transition CEO Leadership to Alnylam President Yvonne Greenstreet at Year End – CAMBRIDGE, Mass.--(BUSINESS WIRE)--
About this update from Alnylam Pharmaceuticals, Inc.
[{"type":"text","content":"\n− Founding Alnylam CEO John Maraganore to Transition CEO Leadership to Alnylam President Yvonne Greenstreet at Year End –\n\n CAMBRIDGE, Mass.--(BUSINESS WIRE)--\nAlnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today the planned CEO transition of John Maraganore, Ph.D., to Yvonne Greenstreet, MBChB, at year-end 2021. Dr. Maraganore joined Alnylam in 2002 as the company’s founding CEO and has led the company’s advancement of RNAi therapeutics as a whole new class of innovative medicines, including four approved medicines marketed in over 25 countries around the world. Dr. Greenstreet joined Alnylam in 2016 and currently serves as the company’s President and COO. Dr. Maraganore will support the leadership transition in a consulting capacity through March 31, 2022 and will continue to contribute to Alnylam’s success as a member of the company’s Scientific Advisory Board. Effective immediately, Dr. Greenstreet has been appointed to the Alnylam Board of Directors as part of the planned succession.\nThis press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211028005382/en/John Maraganore, Ph.D., Chief Executive Officer of Alnylam (Photo: Business Wire)\n“My long-standing tenure at Alnylam has comprised a remarkable journey of conquering the challenges of early science to create an entire new frontier of medicine with multiple RNAi therapeutics helping patients around the world. I am so grateful to have worked with so many outstanding past and present colleagues and collaborators in advancing Alnylam’s Vision and Mission, building a top biopharmaceutical company, while preparing for an exciting future with Alnylam P5x25,” said John Maraganore, Ph.D., Chief Executive Officer of Alnylam. “I have decided that this is the right time to transition my leadership at year end to focus my next chapter on helping other entrepreneurs and companies advance new frontiers of medicine. I couldn’t be more excited about Alnylam’s future under Yvonne’s leadership, and am more confident than ever in the company’s prospects.”\n\n“On behalf of Alnylam’s Board, we are deeply grateful to John’s remarkable and storied leadership of Alnylam for all these years. There’s no doubt that John is both the architect and the inspiration of Alnylam’s success to this poin...